Cargando…

Expansion of opiate agonist treatment: an historical perspective

Untreated opiate addiction remains a major health care crisis in New York and in most other urban centers in America. Optimism for closing the gap between need and demand for treatment and its availability has greeted the recent approval of a new opiate medication for addiction, buprenorphine – whic...

Descripción completa

Detalles Bibliográficos
Autor principal: Newman, Robert G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557846/
https://www.ncbi.nlm.nih.gov/pubmed/16859549
http://dx.doi.org/10.1186/1477-7517-3-20
_version_ 1782129420801146880
author Newman, Robert G
author_facet Newman, Robert G
author_sort Newman, Robert G
collection PubMed
description Untreated opiate addiction remains a major health care crisis in New York and in most other urban centers in America. Optimism for closing the gap between need and demand for treatment and its availability has greeted the recent approval of a new opiate medication for addiction, buprenorphine – which unlike methadone may be prescribed by independent, office-based practitioners. The likelihood of buprenorphine fulfilling its potential is assessed in the light of the massive expansion of methadone treatment more than 30 years earlier. It is concluded that the key, indispensable ingredient of success will be true commitment on the part of Government to provide care to all those who need it.
format Text
id pubmed-1557846
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15578462006-09-01 Expansion of opiate agonist treatment: an historical perspective Newman, Robert G Harm Reduct J Commentary Untreated opiate addiction remains a major health care crisis in New York and in most other urban centers in America. Optimism for closing the gap between need and demand for treatment and its availability has greeted the recent approval of a new opiate medication for addiction, buprenorphine – which unlike methadone may be prescribed by independent, office-based practitioners. The likelihood of buprenorphine fulfilling its potential is assessed in the light of the massive expansion of methadone treatment more than 30 years earlier. It is concluded that the key, indispensable ingredient of success will be true commitment on the part of Government to provide care to all those who need it. BioMed Central 2006-07-21 /pmc/articles/PMC1557846/ /pubmed/16859549 http://dx.doi.org/10.1186/1477-7517-3-20 Text en Copyright © 2006 Newman; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Newman, Robert G
Expansion of opiate agonist treatment: an historical perspective
title Expansion of opiate agonist treatment: an historical perspective
title_full Expansion of opiate agonist treatment: an historical perspective
title_fullStr Expansion of opiate agonist treatment: an historical perspective
title_full_unstemmed Expansion of opiate agonist treatment: an historical perspective
title_short Expansion of opiate agonist treatment: an historical perspective
title_sort expansion of opiate agonist treatment: an historical perspective
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557846/
https://www.ncbi.nlm.nih.gov/pubmed/16859549
http://dx.doi.org/10.1186/1477-7517-3-20
work_keys_str_mv AT newmanrobertg expansionofopiateagonisttreatmentanhistoricalperspective